SCHEMBL3133771

SCHEMBL3133771

Cn1ncc2c1CCCc1c(O)nc(N)nc1-2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.47
CSNK2A1 P68400 1/20 0.47
PLK3 Q9H4B4 1/20 0.47
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
NPC1 O15118 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
HRH4 Q9H3N8 6/20 0.33
HRH3 Q9Y5N1 3/20 0.32
HRH2 P25021 1/20 0.32
HRH1 P35367 1/20 0.32
HCRTR1 O43613 1/20 0.31
GAA P10253 1/20 0.31
MAPK1 P28482 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3143808 0.83 HSD11B1 (0.35) ALDH1A1KDM4EHRH4
SCHEMBL3147608 0.79 HRH4 (0.57) PLK1CSNK2A1PLK3HRH4HRH3
SCHEMBL3147153 0.79 NPC1 (0.51) ALDH1A1KDM4ENPC1HPGDHRH4
SCHEMBL614805 0.74 HRH4 (0.62) PLK1CSNK2A1PLK3HRH4HRH3
SCHEMBL9533936 0.72 PLK1 (0.74) PLK1CSNK2A1PLK3ALDH1A1KDM4E
SCHEMBL4869436 0.70 TYMS (0.39) ALDH1A1KDM4EHRH4HRH3HRH2
SCHEMBL2167222 0.69 HRH4 (0.57) ALDH1A1KDM4ENPC1HRH4HRH3
SCHEMBL4868863 0.69 HRH4 (0.42) ALDH1A1KDM4ENPC1HRH4HRH3
SCHEMBL3133877 0.68 NOS2 (0.38) KDM4ENPC1HRH4HRH3HRH2
SCHEMBL3131633 0.68 HRH4 (0.32) KDM4EHRH4HRH3HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 PLK1 853/4885CSNK2A1 2370/4885PLK3 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.